Comment on ‘Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study’: reply from authors

Authors


  • Funding sources: the research reported in our original paper was supported by the Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre award to Guy's and St Thomas’ NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. The study was also supported by a research grant from the Psoriasis Association, U.K. and by assays provided by Theradiag.

  • Conflicts of interest: one author of the original article has sat on advisory boards for Abbott, Amgen, Celgene, Eli-Lilly, Merck, Novartis and Pfizer.

No abstract is available for this article.

Ancillary